Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

被引：0

作者：

Bringhen, Sara ^{[1
]}

Antonioli, Elisabetta ^{[2
]}

Gamberi, Barbara ^{[3
]}

Bruno, Benedetto ^{[4
,5
]}

Derudas, Daniele ^{[6
]}

Tosi, Patrizia ^{[7
]}

Fazio, Francesca ^{[8
]}

Mazza, Rita ^{[9
]}

Ronconi, Sonia ^{[10
]}

Corradini, Paolo ^{[11
]}

Lotti, Flavia ^{[12
]}

Cellini, Claudia ^{[13
]}

Falcone, Antonietta Pia ^{[14
]}

Galieni, Piero ^{[15
]}

Ria, Roberto ^{[16
]}

Belotti, Angelo ^{[17
]}

Mannina, Donato

Cafro, Anna Maria ^{[18
,19
]}

Cangialosi, Clotilde ^{[20
]}

Vincelli, Iolanda Donatella ^{[21
]}

Lombardo, Alessandra ^{[22
]}

Larocca, Alessandra ^{[1
,5
]}

Boccadoro, Mario ^{[23
]}

D'Agostino, Mattia ^{[4
,5
]}

机构：

[1] Azienda Osped Univ Citta Salute Scienza Torino, SSD Clin Trial Oncoematol Mieloma Multiplo, Dept Oncol, Turin, Italy

[2] AOU Careggi, Hematol Unit, Florence, Italy

[3] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[4] Univ Torino, Azienda Osped Univ Citta Salute Scienza Torino, Div Hematol, Turin, Italy

[5] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[6] SC Ematol CTMO, Osped Oncol Riferimento Reg Businco ARNAS G Brotz, Cagliari, Italy

[7] Osped Rimini, UO Ematol, Rimini, Italy

[8] Sapienza Univ Rome, Hematol, Dept Translat & Precis Med, Rome, Italy

[9] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Dept Hematol & Oncol, Rozzano, Italy

[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[11] Univ Milan, Hematol Div, Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy

[12] Osped Santa Maria Misericordia, Sezione Ematol & Immunol Clin, Perugia, Italy

[13] Osped Santa Maria Croci, AUSL Romagna, UOC Ematol Osped Santa Maria Croci, Ravenna, Italy

[14] IRCCS Casa Sollievo Sofferenza, Hematol, San Giovanni Rotondo, Italy

[15] Osped CG Mazzoni, UOC Ematol & Terapia Cellulare, Ascoli Piceno, Italy

[16] Univ Bari, Aldo Moro Med Sch, Dept Precis & Regenerat Med & Ionian Area DiMePRe, Bari, Italy

[17] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[18] Papardo Hosp, Oncol Hematol Dept, Messina, Italy

[19] ASST GOM Niguarda, SC Ematol, Milan, Italy

[20] AO Osped Riuniti Villa Sofia Cervello, UOC Ematol, Palermo, Italy

[21] Grande Osped Metropolitano Bianchi Melacrino More, Hematol Unit, Dept Hemato Oncol & Radiotherapy, Reggio Di Calabria, Italy

[22] AO Santa Maria Terni, SC Oncoematol, Terni, Italy

[23] European Myeloma Network, EMN, Turin, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177673

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 42 条

[1] Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial
D'Agostino, Mattia
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Carlo-Stella, Carmelo
Ronconi, Sonia
Corradini, Paolo
Ballanti, Stelvio
Cellini, Claudia
Falcone, Antonietta Pia
Bringhen, Sara
Offidani, Massimo
Rambaldi, Alessandro
Rota-Scalabrini, Delia
Agazzi, Alberto
Casaluci, Gloria Margiotta
Pietrantuono, Giuseppe
Patriarca, Francesca
Larocca, Alessandra
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S94 - S95
[2] Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).
Derman, Benjamin Avi
Zonder, Jeffrey A.
Kansagra, Ankit J.
Grinblatt, David L.
Narula, Sunil
Rayani, Shayan
Stefka, Andrew T.
Jiang, Ken
Major, Sarah
Wolfe, Brittany
Whelan, Megan
Libao, Bernadette
McIver, Amanda
Andreatos, Evangelia
Juergens, Daniel
Alcantar, Luis
Karrison, Theodore
Bishop, Michael Russell
Jasielec, Jagoda
Jakubowiak, Andrzej J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Stem-Cell Mobilization and Transplantation in Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib-Lenalidomide-Dexamethasone With or Without Isatuximab: Results From the IsKia Trial
Mina, Roberto
Gay, Francesca
Roeloffzen, Wilfried
Dimopoulos, Meletios
Rosinol, Laura
van der Klift, Marjolein
Oriol, Albert
Katodritou, Eirini
Wu, Ka Lung
Rodriguez-Otero, Paula
Hajek, Roman
Mangiacavalli, Silvia
van Duin, Mark
D'Agostino, Mattia
de Waal, Esther
Ocio, Enrique
Levin, Mark-David
Mateos Manteca, Maria-Victoria
Slordahl, Tobias
Schjesvold, Fredrik
Blade, Joan
Einsele, Hermann
Sonneveld, Pieter
Boccadoro, Mario
Broijl, Annemiek
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S236 - S237
[4] Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Gay, Francesca
Roeloffzen, Wilfried
Dimopoulos, Meletios A.
Rosinol, Laura
van der Klift, Marjolein
Mina, Roberto
Oriol Rocafiguera, Albert
Katodritou, Eirini
Wu, Ka Lung
Rodriguez Otero, Paula
Hajek, Roman
Antonioli, Elisabetta
van Duin, Mark
D'Agostino, Mattia
Martinez-Lopez, Joaquin
van Leeuwen-Segarceanu, Elena M.
Tacchetti, Paola
van de Donk, Niels W. C. J.
Weisel, Katja
Pour, Ludek
Radocha, Jakub
Belotti, Angelo
Schjesvold, Fredrik
Blade, Joan
Einsele, Hermann
Sonneveld, Pieter
Boccadoro, Mario
Broijl, Annemiek
BLOOD, 2023, 142
[5] Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Kubicki, Tadeusz
Dytfeld, Dominik
Wrobel, Tomasz
Jamroziak, Krzysztof
Robak, Pawel
Czyz, Jaroslaw
Tyczynska, Agata
Druzd-Sitek, Agnieszka
Giannopoulos, Krzysztof
Nowicki, Adam
Szczepaniak, Tomasz
Lojko-Dankowska, Anna
Matuszak, Magdalena
Gil, Lidia
Pula, Bartosz Michal
Rybka, Justyna
Majcherek, Maciej
Usnarska-Zubkiewicz, Lidia
Szukalski, Lukasz
Konska, Agnieszka
Zaucha, Jan M.
Walewski, Jan
Mikulski, Damian
Czabak, Olga
Robak, Tadeusz
Kruk-Kwapisz, Dorota
Lahoud, Oscar Boutros
Zonder, Jeffrey A.
Griffith, Kent
Stefka, Andrew T.
Jiang, Ken
Cooperrider, Jennifer H.
Derman, Ben A.
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[6] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
Derman, Benjamin A.
Cooperrider, Jennifer H.
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Major, Ajay
Karrison, Theodore
Jiang, Ken
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[7] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
Gay, Francesca
Cerrato, Chiara
Scalabrini, Delia Rota
Galli, Monica
Belotti, Angelo
Zamagni, Elena
Ledda, Antonio
Grasso, Mariella
Angelucci, Emanuele
Liberati, Anna Marina
Tosi, Patrizia
Pisani, Francesco
Spada, Stefano
Annibali, Ombretta
Baraldi, Anna
Omede, Paola
Galieni, Piero
Rizzi, Rita
Pescosta, Norbert
Ronconi, Sonia
Vincelli, Donatella
Cafro, Anna Maria
Offidani, Massimo
Palumbo, Antonio
Musto, Pellegrino
Cavo, Michele
Boccadoro, Mario
BLOOD, 2018, 132
[8] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Zimmerman, Todd
Raje, Noopur S.
Vij, Ravi
Reece, Donna
Berdeja, Jesus G.
Stephens, Leonor A.
McDonnell, Kathryn
Rosenbaum, Cara A.
Jasielec, Jagoda
Richardson, Paul G.
Gurbuxani, Sandeep
Nam, Jennifer
Severson, Erica
Wolfe, Brittany D.
Rosebeck, Shaun
Stefka, Andrew
Dytfeld, Dominik
Griffith, Kent
Jakubowiak, Andrzej
BLOOD, 2016, 128 (22)
[9] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[10] Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
Derman, Benjamin A.
Stefka, Andrew T.
Jiang, Ken
McIver, Amanda
Kubicki, Tadeusz
Jasielec, Jagoda K.
Jakubowiak, Andrzej J.
BLOOD CANCER JOURNAL, 2021, 11 (02)

← 1 2 3 4 5 →